Related Experiment Video
Updated: Sep 23, 2025

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol
Hanene Lassoued Ferjani1,2,3, Yasmine Makhlouf1,2, Kaouther Maatallah1,2,3
1Department of Rheumatology, Mohammed Kassab National Institute of Orthopedics Mannouba, Tunisia.
Insights
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare pediatric autoinflammatory bone disorder. Current management focuses on NSAIDs, with bisphosphonates for vertebral involvement and anti-TNF agents showing promise.
Area of Science:
- Pediatric rheumatology
- Autoinflammatory diseases
- Osteomyelitis
Background:
- Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory condition primarily affecting children.
- It typically presents with peripheral metaphyseal bone involvement, distinguishing it from other osteomyelitis types.
- Lack of established management guidelines complicates CRMO treatment.
Purpose of the Study:
- To review current therapeutic strategies for CRMO.
- To discuss first-line, second-line, and emerging treatments for this condition.
- To provide an overview of recent management protocols.
Main Methods:
- Literature search conducted on PubMed focusing on CRMO.
- Review of studies examining therapeutic alternatives and outcomes.
- Categorization of treatments into first-line and second-line approaches.
Main Results:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary first-line treatment for CRMO.
- Bisphosphonates are recommended as a first-line option for vertebral CRMO.
- Anti-TNF agents demonstrate efficacy, particularly in CRMO with co-occurring immune-mediated diseases.
Conclusions:
- NSAIDs form the cornerstone of CRMO management.
- Bisphosphonates and anti-TNF agents represent important therapeutic options for specific CRMO presentations.
- Further research is needed to clarify the role of interleukin-1 antagonists in CRMO treatment.
Introduction:
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory disorder primarily affecting children. It is characterized by a peripheral involvement of the metaphysis of long bones rather than axial involvement. Due to the scarcity of the disease, there are no guidelines regarding its management.
Areas Covered:
This review aims to provide an overview of the different therapeutic alternatives and recent protocols. For this reason, first-line and second-line treatment, as well as the impact of new therapies, are discussed in depth. We conducted a search through PubMed on the different aspects of CRMO. Outcomes were categorized as first and second-line treatments.
Expert Opinion:
Non-steroidal anti-inflammatory drugs remain the keystone of CRMO management and are proposed as the first-line treatment. In the case of vertebral involvement, bisphosphonate should be considered, even as a first-line treatment. Several case series and retrospective studies highlight the efficacy of anti-TNF agents. Their use could be an optimal treatment choice for CRMO with comorbid immune-mediated diseases. The potentially favorable effect of interleukin-1 antagonists remains to be determined.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis III: Medical Management
Tonsillitis II: Management
Myocarditis IV: Nursing Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Mitral Stenosis III: Medical Management

